|
|
PCV
chemotherapy for recurrent glioblastoma multiforme
Kappelle
AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ,
Zonnenberg BA, Sneeuw KC, Heimans JJ
Departments
of Neurology and Medical Oncology, University Hospital Vrije Universiteit,
Amsterdam, The Netherlands
The
authors evaluated response, time to progression (TTP), survival, prognostic
factors, and toxicity in 63 patients with a
recurrent glioblastoma multiforme treated with procarbazine, lomustine, and
vincristine (PCV) chemotherapy.
Complete and partial response was observed in two (3%) and five patients
(8%).
In 16 patients (25%), stable disease was observed.
Median TTP and survival were 13 and 33 weeks.
Age < 40 years and Karnofsky Performance Status > or = 90 were associated
with longer TTP and survival.
PCV treatment was generally well tolerated.
PMID:
11148250 [PubMed - indexed for MEDLINE]
|
